OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation in autoimmune diseases
Paris, Nantes, July 5, 2016 – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo : OSE), an immunotherapy company developing activating or regulating immunotherapies in immuno-oncology, autoimmune diseases and transplantation, is pleased to announce the exercise by Janssen Biotech, Inc. (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) of the option within the global license agreement between Janssen and OSE Immunotherapeutics. Under the terms of this agreement, Janssen will be responsible for all clinical development, registration and commercialization activities for FR104, internationally, in the areas of autoimmune diseases and transplantation. The deal was facilitated by Effimune and Johnson & Johnson Innovation’s London Innovation Centre in October 2013.